

## EQA round: IHC2/23 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 8.9.2023

Setup: groups - manufacturer of kit

AV = assigned value

N<sub>tot</sub> = total number of the resultsN<sub>eva</sub> = number of the results assessedN<sub>rel</sub> = relative number of the resultsN<sub>suc</sub> = number of successful results

CVE = consensus of the experts

S<sub>rel</sub> = relative success

&gt;&gt;&gt; ... expected result

&gt; ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results					Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
<b>(601) A1 expression HER-2/neu</b>		49			49	49	100	
<b>Slide</b>		49			49	49	100	
(802) Dako HercepTest	CVE >>>	8	16	Strong positive (3+)				
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	12	24	Strong positive (3+)				
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	27	55	Strong positive (3+)				
(999) another manufacturer	CVE >>>	2	4,1	Strong positive (3+)				
<b>(602) A2 expression HER-2/neu</b>		49			49	48	98	
<b>Slide</b>		49			49	48	98	
(802) Dako HercepTest	CVE >>>	6	12	Negative (0)				
	>	1	2	Negative (1+)				
		1	2	Weak positive (2+)				
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	9	18	Negative (0)				
	>	3	6,1	Negative (1+)				
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	27	55	Negative (0)				
(999) another manufacturer	CVE >>>	2	4,1	Negative (0)				
<b>(603) A3 expression HER-2/neu</b>		49			49	40	82	
<b>Slide</b>		49			49	40	82	
(802) Dako HercepTest	CVE >>>	6	12	Weak positive (2+)				
	>	2	4,1	Strong positive (3+)				
(803) Dako c-erbB-2 Onkoprotein		1	2	Negative (1+)				
	CVE >>>	8	16	Weak positive (2+)				
	>	3	6,1	Strong positive (3+)				
(804) Ventana PATHWAY anti-HER-2/neu		7	14	Negative (1+)				
	CVE >>>	20	41	Weak positive (2+)				
(999) another manufacturer		1	2	Negative (1+)				
	CVE >>>	1	2	Weak positive (2+)				
<b>(606) B1 expression HER-2/neu</b>		49			0			
<b>Slide</b>		49			0			
(802) Dako HercepTest	±	1	2	Negative (1+)				
	±	7	14	Weak positive (2+)				
(803) Dako c-erbB-2 Onkoprotein	±	3	6,1	Negative (1+)				
	±	9	18	Weak positive (2+)				
(804) Ventana PATHWAY anti-HER-2/neu	±	18	37	Negative (1+)				
	±	9	18	Weak positive (2+)				
(999) another manufacturer	±	2	4,1	Negative (1+)				
<b>(607) B2 expression HER-2/neu</b>		49			49	49	100	
<b>Slide</b>		49			49	49	100	
(802) Dako HercepTest	CVE >>>	5	10	Weak positive (2+)				
	>	3	6,1	Strong positive (3+)				
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	5	10	Weak positive (2+)				
	>	7	14	Strong positive (3+)				
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	21	43	Weak positive (2+)				
	>	6	12	Strong positive (3+)				
(999) another manufacturer	CVE >>>	2	4,1	Weak positive (2+)				
<b>(608) B3 expression HER-2/neu</b>		49			0			
<b>Slide</b>		49			0			
(802) Dako HercepTest	±	3	6,1	Negative (1+)				
	±	5	10	Weak positive (2+)				
(803) Dako c-erbB-2 Onkoprotein	±	4	8,2	Negative (1+)				
	±	8	16	Weak positive (2+)				
(804) Ventana PATHWAY anti-HER-2/neu	±	11	22	Negative (1+)				
	±	16	33	Weak positive (2+)				
(999) another manufacturer	±	2	4,1	Negative (1+)				
<b>(611) C1 expression HER-2/neu</b>		49			0			
<b>Slide</b>		49			0			
(802) Dako HercepTest	±	7	14	Negative (1+)				
	±	1	2	Weak positive (2+)				
(803) Dako c-erbB-2 Onkoprotein	±	7	14	Negative (1+)				
	±	4	8,2	Weak positive (2+)				
	±	1	2	Strong positive (3+)				
(804) Ventana PATHWAY anti-HER-2/neu	±	13	27	Negative (1+)				
	±	14	29	Weak positive (2+)				
(999) another manufacturer	±	1	2	Negative (1+)				
	±	1	2	Weak positive (2+)				

## EQA round: IHC2/23 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 8.9.2023

Setup: groups - manufacturer of kit

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
<b>(612) C2 expression HER-2/neu</b>		49			49	44	90
<b>Slide</b>		49			49	44	90
(802) Dako HercepTest	CVE >>>	2	4,1	Negative (0)			
	CVE >>>	3	6,1	Negative (1+)			
		3	6,1	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	3	6,1	Negative (0)			
	CVE >>>	7	14	Negative (1+)			
		2	4,1	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	18	37	Negative (0)			
	CVE >>>	9	18	Negative (1+)			
(999) another manufacturer	CVE >>>	1	2	Negative (0)			
	CVE >>>	1	2	Negative (1+)			
<b>(613) C3 expression HER-2/neu</b>		49			49	49	100
<b>Slide</b>		49			49	49	100
(802) Dako HercepTest	CVE >>>	8	16	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	11	22	Weak positive (2+)			
	>	1	2	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	24	49	Weak positive (2+)			
	>	3	6,1	Strong positive (3+)			
(999) another manufacturer	CVE >>>	2	4,1	Weak positive (2+)			
<b>(616) D1 expression HER-2/neu</b>		48			48	46	96
<b>Slide</b>		48			48	46	96
(802) Dako HercepTest	CVE >>>	7	15	Negative (0)			
	CVE >>>	1	2,1	Negative (1+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	6	13	Negative (0)			
	CVE >>>	4	8,3	Negative (1+)			
		1	2,1	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	10	21	Negative (0)			
	CVE >>>	16	33	Negative (1+)			
		1	2,1	Weak positive (2+)			
(999) another manufacturer	CVE >>>	2	4,2	Negative (0)			
<b>(617) D2 expression HER-2/neu</b>		49			0		
<b>Slide</b>		49			0		
(802) Dako HercepTest	±	4	8,2	Negative (1+)			
	±	4	8,2	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	±	2	4,1	Negative (1+)			
	±	9	18	Weak positive (2+)			
	±	1	2	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	±	10	20	Negative (1+)			
	±	17	35	Weak positive (2+)			
(999) another manufacturer	±	1	2	Negative (1+)			
	±	1	2	Weak positive (2+)			
<b>(618) D3 expression HER-2/neu</b>		49			0		
<b>Slide</b>		49			0		
(802) Dako HercepTest	±	1	2	Negative (1+)			
	±	7	14	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	±	3	6,1	Negative (1+)			
	±	8	16	Weak positive (2+)			
	±	1	2	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	±	5	10	Negative (1+)			
	±	22	45	Weak positive (2+)			
(999) another manufacturer	±	2	4,1	Weak positive (2+)			
<b>(621) E1 expression HER-2/neu</b>		49			49	48	98
<b>Slide</b>		49			49	48	98
(802) Dako HercepTest	CVE >>>	2	4,1	Negative (0)			
	CVE >>>	5	10	Negative (1+)			
		1	2	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	3	6,1	Negative (0)			
	CVE >>>	9	18	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	18	37	Negative (0)			
	CVE >>>	9	18	Negative (1+)			
(999) another manufacturer	CVE >>>	2	4,1	Negative (0)			
<b>(622) E2 expression HER-2/neu</b>		49			49	49	100
<b>Slide</b>		49			49	49	100
(802) Dako HercepTest	CVE >>>	7	14	Negative (0)			
	CVE >>>	1	2	Negative (1+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	8	16	Negative (0)			
	CVE >>>	4	8,2	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	14	29	Negative (0)			

## EQA round: IHC2/23 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 8.9.2023

Setup: groups - manufacturer of kit

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
(999) another manufacturer	CVE >>>	13	27	Negative (1+)			
	CVE >>>	2	4,1	Negative (0)			
<b>(623) E3 expression HER-2/neu</b>		48			48	48	100
<b>Slide</b>		48			48	48	100
(802) Dako HercepTest	CVE >>>	8	17	Negative (0)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	11	23	Negative (0)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	27	56	Negative (0)			
(999) another manufacturer	CVE >>>	2	4,2	Negative (0)			